Table 2.
Secondary outcomes
| Secondary outcomes | Number of studies (Reference no.) | Patients in Midazolam group (Incidence, %) | Patients in Ketamine group (Incidence, %) | I2 (%) | Risk ratio with [95% CI] | P value |
|---|---|---|---|---|---|---|
| Nauseas and vomiting | 4 [23, 26, 28, 29] | 16/185 (8.65%) | 23/185 (12.43%) | 66 | 0.89 [0.21, 3.69] | 0.87 |
| Agitation | 3 [26, 28, 29] | 16/155 (10.32%) | 11/155 (7.10%) | 0 | 1.45 [0.71, 2.94] | 0.30 |
| Oxygen saturation below 90% | 1 [18] | 0/10 (0.00%) | 2/10 (20.00%) | - | - | - |
| Secondary outcomes | Number of studies (Reference no.) | Number of patients in Midazolam group | Number of patients in Ketamine group | I2 (%) | Standardized Mean difference with [95% CI] | P value |
| Onset of sedation | 3 [15, 21, 22] | 80 | 86 | 0 | -0.59 [-0.90, -0.28] | 0.0002* |
| Recovery time | 3 [22, 24, 28] | 86 | 87 | 82 | -1.06 [-1.83, -0.28] | 0.008* |
| Heart rate (HR) | 4 [21, 24–26] | 152 | 151 | 96 | -1.39 [-2.84, 0.06] | 0.06 |
| Systolic blood pressure (SBP) | 1 [21] | 32 | 32 | - | - | - |
| Mean blood pressure (MBP) | 2 [24, 25] | 50 | 50 | 0 | -0.53 [-0.93, -0.13] | 0.009* |
| Oxygen saturation | 2 [21, 24] | 62 | 62 | 57 | -0.57 [-1.13, -0.02] | 0.04* |